











































Protocol for the development of the international population
registry for aphasia after stroke (I-PRAISE)
Citation for published version:
Ali, M, Ben Basat, AL, Berthier, M, Blom Johansson, M, Breitenstein, C, Cadilhac, DA, Constantinidou, F,
Cruice, M, Davila, G, Gandolfi, M, Gil, M, Grima, R, Godecke, E, Jesus, L, Jiminez, LM, Kambanaros, M,
Kukkonen, T, Laska, A, Mavis, I, Mc Menamin, R, Mendez-orellana, C, Obrig, H, Ostberg, P, Robson, H,
Sage, K, Van De Sandt-koenderman, M, Sprecht, K, Visch-brink, E, Wehling, E, Wielaert, S, Wallace, SJ,
Williams, LJ & Brady, MC 2021, 'Protocol for the development of the international population registry for
aphasia after stroke (I-PRAISE)', Aphasiology, pp. 1-21. https://doi.org/10.1080/02687038.2021.1914813
Digital Object Identifier (DOI):
10.1080/02687038.2021.1914813
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:




Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 23. Jul. 2021
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=paph20
Aphasiology
ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/paph20
Protocol for the development of the international
population registry for aphasia after stroke (I-
PRAISE)
M Ali, A Lifshitz Ben Basat, M Berthier, M Blom Johansson, C Breitenstein, D
A Cadilhac, F Constantinidou, M Cruice, G Davila, M Gandolfi, M Gil, R Grima,
E Godecke, L Jesus, L Martinez Jiminez, M Kambanaros, T Kukkonen, A Laska,
I Mavis, R Mc Menamin, C Mendez-Orellana, H Obrig, P Ostberg, H Robson,
K Sage, M Van De Sandt-Koenderman, K Sprecht, E Visch-Brink, E Wehling, S
Wielaert, S J Wallace, L J Williams & M C Brady
To cite this article: M Ali, A Lifshitz Ben Basat, M Berthier, M Blom Johansson, C Breitenstein, D A
Cadilhac, F Constantinidou, M Cruice, G Davila, M Gandolfi, M Gil, R Grima, E Godecke, L Jesus,
L Martinez Jiminez, M Kambanaros, T Kukkonen, A Laska, I Mavis, R Mc Menamin, C Mendez-
Orellana, H Obrig, P Ostberg, H Robson, K Sage, M Van De Sandt-Koenderman, K Sprecht,
E Visch-Brink, E Wehling, S Wielaert, S J Wallace, L J Williams & M C Brady (2021): Protocol
for the development of the international population registry for aphasia after stroke (I-PRAISE),
Aphasiology, DOI: 10.1080/02687038.2021.1914813
To link to this article:  https://doi.org/10.1080/02687038.2021.1914813
© 2021 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group.
Published online: 27 Jun 2021.
Submit your article to this journal Article views: 334
View related articles View Crossmark data
Protocol for the development of the international population 
registry for aphasia after stroke (I-PRAISE)
M Ali a, A Lifshitz Ben Basatb, M Berthierc, M Blom Johansson d, C Breitenstein e, 
D A Cadilhac f, F Constantinidoug, M Cruice h, G Davilai, M Gandolfi j, M Gilk, 
R Grimal, E Godecke m, L Jesus n, L Martinez Jiminezo, M Kambanarosp, 
T Kukkonen q, A Laska r, I Mavis s, R Mc Menamin t, C Mendez-Orellanau, 
H Obrigv, P Ostberg w, H Robsonx, K Sagey, M Van De Sandt-Koenderman z, 
K Sprecht aa, E Visch-Brink bb, E Wehlingcc, S Wielaertz, S J Wallace dd, 
L J Williams ee and M C Brady a
aNMAHP Research Unit, Glasgow Caledonian University, Glasgow, UK; bDepartment of Communication 
Disorders, Ariel University, Ariel, Israel; cCognitive Neurology and Aphasia Unit, Centro De Investigaciones 
Médico-Sanitarias, Instituto De Investigación Biomédica De Málaga (IBIMA), University of Malaga, Malaga, 
Spain; dDepartment of Neuroscience, Speech-Language Pathology, Uppsala University, Uppsala, Sweden; 
eDept. Of Neurology with Institute of Translational Neurology, University of Muenster, Germany; 
fDepartment of Medicine, School of Clinical Sciences at Monash Health, Monash University, Australia; 
gDepartment of Psychology and Center for Applied Neuroscience, University of Cyprus Nicosia, Cyprus; hCity, 
University of London, London, UK; iCognitive Neurology and Aphasia Unit, Centro De Investigaciones 
Médico-Sanitarias, Instituto De Investigación Biomédica De Málaga (IBIMA), University of Malaga, Malaga, 
Spain Area of Psychobiology, Faculty of Psychology and Speech Therapy, University of Malaga, Malaga, 
Spain; jDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, 
Italy; kDepartment of Communication Disorders, Loewenstein Rehabilitation Hospital, Israel; lDepartment of 
Communication Therapy, Faculty of Health Sciences, University of Malta Imsida, Malta; mSchool of Medical 
and Health Sciences, Edith Cowan University, Australia; Speech Pathology Department, Sir Charles Gairdner 
Hospital, Australia & Centre for Research Excellence in Aphasia Recovery and Rehabilitation, Melbourne, 
Australia; nSchool of Health Sciences (ESSUA) and Institute of Electronics and Informatics Engineering of 
Aveiro (IEETA), University of Aveiro, Portugal; oUniversidad De Talca, Talca, Chile; pAllied Health and Human 
Performance, University of South Australia, Adelaide South, Australia; qDepartment of ENT/Phoniatry, 
Pirkanmaa Hospital District, Tampere University Hospital, Tampere, Finland; rDepartment of Clinical 
Sciences, Danderyd Hospital, Karolinska Institute, Stockholm, Sweden; sSpeech and Language Therapy 
Department, Anadolu University, Eskişehir, Turkey; tDiscipline of Speech and Language Therapy, School of 
Health Sciences, National University of Ireland, Galway, Ireland; uCarrera De Fonoaudiología, Departamento 
Ciencias De La Salud, Facultad De Medicina, Pontificia Universidad Católica De Chile, Santiago- Chile; vClinic 
for Cognitive Neurology, University Hospital Leipzig & MPI for Human Cognitive and Brain Sciences, Leipzig, 
Germany; wDepartment of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institute, 
Stockholm, Sweden; xPsychology and Language Sciences, University College London, London, UK; 
yDepartment of Nursing, Faculty of Health, Psychology and Social Care, Manchester Metropolitan University 
UK; zDept of Rehabilitation Medicine, Rijndam Rehabilitation Centre & Erasmus MC, Rotterdam, The 
Netherlands; aaDepartment of Biological and Medical Psychology, Faculty of Psychology, University of 
Bergen, Bergen Norway; bbDepartment of Neurology and Neurosurgery, Erasmus University Medical Center, 
Rotterdam, Netherlands; ccDepartment of Physical Medicine and Rehabilitation, Haukeland University 
Hospital, Bergen, Norway; ddQueensland Aphasia Research Centre, School of Health and Rehabilitation 
Sciences, the University of Queensland, Brisbane, Australia; eeUsher Institute, University of Edinburgh, UK
CONTACT M Ali Myzoon.ali@gcu.ac.uk NMAHP Research Unit, Glasgow Caledonian University, A433 Govan 
Mbeki Building, G4 0BA.
APHASIOLOGY                                               
https://doi.org/10.1080/02687038.2021.1914813
© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/ 
licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly 
cited.
ABSTRACT
Background: We require high-quality information on the current 
burden, the types of therapy and resources available, methods of 
delivery, care pathways and long-term outcomes for people with 
aphasia.
Aim: To document and inform international delivery of post-stroke 
aphasia treatment, to optimise recovery and reintegration of peo-
ple with aphasia.
Methods & Procedures: Multi-centre, prospective, non-rando-
mised, open study, employing blinded outcome assessment, 
where appropriate, including people with post-stroke aphasia, 
able to attend for 30 minutes during the initial language assess-
ment, at first contact with a speech and language therapist for 
assessment of aphasia at participating sites. There is no study- 
mandated intervention. Assessments will occur at baseline (first 
contact with a speech and language therapist for aphasia assess-
ment), discharge from Speech and Language Therapy (SLT), 6 and 
12-months post-stroke. Our primary outcome is changed from 
baseline in the Amsterdam Nijmegen Everyday Language Test 
(ANELT/Scenario Test for participants with severe verbal impair-
ments) at 12-months post-stroke. Secondary outcomes at 6 and 
12 months include the Therapy Outcome Measure (TOMS), 
Subjective Index of Physical and Social Outcome (SIPSO), Aphasia 
Severity Rating Scale (ASRS), Western Aphasia Battery Aphasia 
Quotient (WAB-AQ), stroke and aphasia quality of life scale 
(SAQoL-39), European Quality of Life Scale (EQ-5D), lesion descrip-
tion, General Health Questionnaire (GHQ-12), resource use, and 
satisfaction with therapy provision and success. We will collect 
demography, clinical data, and therapy content. Routine neuroima-
ging and medication administration records will be accessed where 
possible; imaging will be pseudonymised and transferred to a 
central reading centre. Data will be collected in a central registry. 
We will describe demography, stroke and aphasia profiles and 
therapies available. International individual participant data (IPD) 
meta-analyses will examine treatment responder rates based on 
minimal detectable change & clinically important changes from 
baseline for primary and secondary outcomes at 6 and 12 months. 
Multivariable meta-analyses will examine associations between 
demography, therapy, medication use and outcomes, considering 
service characteristics. Where feasible, costs associated with treat-
ment will be reported. Where available, we will detail brain lesion 
size and site, and examine correlations with SLT and language 
outcome at 12 months.
Conclusion: International differences in care, resource utilisation 
and outcomes will highlight avenues for further aphasia research, 
promote knowledge sharing and optimise aphasia rehabilitation 
delivery. IPD meta-analyses will enhance and expand understand-
ing, identifying cost-effective and promising approaches to opti-
mise rehabilitation to benefit people with aphasia.
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Introduction
People with aphasia are a highly heterogeneous group. Our insight into the relationships 
between recovery patterns and individual participant characteristics (e.g., age, education, 
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mood, cognitive abilities and socioeconomic status), stroke (type, severity and location) and 
aphasia profiles are limited. While some evidence suggests that the above factors are likely to 
influence initial aphasia profile, language recovery and performance on assessment tools, the 
sample sizes are often small and data collection remains inadequate to guide best practice.
Delivery, quality of care, level of support and definitions of standard aphasia care vary 
within and across regions and countries, limiting our ability to build an overall picture of the 
status of aphasia care within a clinically relevant population. Long-term recovery, service 
needs, patient pathways following rehabilitation, referral rates to community support groups, 
adherence to rehabilitation, home-based therapy, access to and the effect of emerging 
community support groups each remain unclear. This has resulted in a poor understanding 
of how these factors may contribute to aphasia outcomes in the clinical population.
Aphasia research and clinical practice would benefit from high-quality information on 
the burden of aphasia, the regional differences in existing practice, which approaches 
work well within the constraints of current capacity, long-term outcomes after post-stroke 
aphasia and what happens to those with aphasia after discharge from speech and 
language therapy (SLT). Implementation of standardised and consistent assessment 
procedures across international clinical settings would facilitate the rapid generation of 
high-quality aphasia data that is comparable across settings, aphasia services, regions and 
countries. Such comparable data could contribute to the establishment of clinical regis-
tries and international stroke trials for post-stroke aphasia outcome and rehabilitation.
Prospective data collection with a standardised protocol that adheres to aphasia Core 
Outcome Set recommendations (Wallace et al., 2019) would accurately and robustly capture 
information on participants, delivery and type of care available within service delivery 
constraints, and third-sector involvement. Collation of these data at individual, therapeutic 
and services levels would identify gaps in the evidence for treatment of aphasia populations, 
current practice for aphasia treatment, geographic differences in care pathways, quality and 
access to care and outcomes. Whilst data from RCTs form the gold standard for efficacy of 
aphasia interventions, these data may exhibit selection bias in the people represented in the 
trials. Prospective data collection in the wider clinical population would supplement and 
expand on evidence from RCTs to provide a broader picture of the aphasia population, the 
state of aphasia care regionally and internationally, and permit analyses of rich, international 
data using predictive models to identify and inform best practice.
Aim
To document and inform international delivery of post-stroke aphasia treatment, to 
optimise recovery and reintegration of people with aphasia into society.
Objectives
To establish national clinical registries for aphasia rehabilitation across the world; indivi-




(1) Which aphasia treatments are used across participating sites (e.g., type, frequency, 
duration) and what are the associated outcomes (e.g., communication and lan-
guage outcomes, discharge destination, referrals, resource use and support service 
access)?
(2) What is the association between baseline demographics, site of enrolment, com-
ponents of care, duration and frequency of any treatments and outcomes at 6 and 
12 months post-stroke?
(3) What is the relationship between lesion size, site and pattern with patho-linguistic 
variables including:
(a) aphasia severity and profile prior to therapy
(b) communication outcome at 6 and 12 months?
(4) What is the relationship between medication administration and therapy outcome 
at 6 months and 12 months post-stroke?
(5) What are participant and carer perceptions of care and intervention success at 
12 months post-stroke?
(6) What are the costs associated with different pathways of care (including staff 
involved, clinical, support services and participant provided services used)?
Methods
Ethics
This project currently involves investigators across 11 countries, with an open invitation 
for others to join. Ethics Committee approval requirements vary between participating 
countries. The study will be carried out in compliance with a shared protocol, and the 
principles laid down in the Declaration of Helsinki, in accordance with the International 
Conference on Harmonisation (ICH) Harmonised Tripartite Guideline for Good Clinical 
Practice (GCP), and in accordance with applicable regulatory requirements. The protocol 
will be submitted for approval to the appropriate Ethics Committee in each participating 
country, centre or regions, as appropriate, and written approval obtained, before partici-
pants are enrolled from that country.
Preparatory & pilot work
Work is underway (Malta IPD = 42, Sweden IPD = 6 & Cyprus IPD = 25) to pilot assessment 
and data collection procedures using a truncated version of the data collection form 
(baseline demographics, stroke severity stroke and aphasia severity, therapy description, 
post-therapy/discharge from SLT, 6 and 12-month aphasia severity and independence). 
Preparatory work is also underway in Chile and Norway to generate language-specific 
adaptations of key assessment tools prior to data collection.
Experience from this work has highlighted the need to take a pragmatic approach to 
recruitment and data acquisition, including permitting data collection not only in 
a population-based (registry) context, but also from research study contexts. Pilot work 
has highlighted recruitment issues within an acute setting, as well as problems recruiting 
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participants to a registry-based study whilst offering only standard care. 
Recommendations include aligning data collection items with planned research studies 
and engaging with routine data collection from stroke registries to maximise data collec-
tion across different countries. These recommendations have been taken forward.
Design
This is a multicentre, prospective, non-randomised study, enrolling a cohort of stroke 
survivors with aphasia across participating international sites.
Data acquisition
Data for I-PRAISE will be acquired using three designs:
(1) Prospective Data Collection in a Registry
Data on demography, therapy and outcomes will be prospectively collected for partici-
pants who are recruited in the acute/early subacute phase after stroke. Baseline assess-
ments will take place at (or as close to) first contact with the speech and language 
therapist. Outcomes will be assessed at discharge, 6 and 12 months post-stroke (Table 
1: Description of assessment tools; Table 2: Schedule of measurements; Figure 1: Study 
overview and data acquisition sources). For participants who’s first contact with SLT is in 
the chronic setting, we will retrospectively access and document data including demo-
graphy, time since stroke and SLT received since stroke onset; outcomes will then be 
prospectively assessed.
Table 1. Description of assessments.
Assessment Instrument Purpose
Aphasia Severity Rating Scale (ASRS) A short measure of overall aphasia severity
Western Aphasia Battery Aphasia 
Quotient (WAB-AQ)
More detailed measure of language ability
Amsterdam Neijmegen Everyday 
Language Test
Functional communication ability in verbal participants
Scenario Test Functional communication ability in severely impaired participants
Therapy Outcome Measure An assessment to describe the relative abilities and difficulties of a patient/ 
client in the four domains of impairment, activity, participation and 
wellbeing in order to monitor changes over time
General Health Quuestionnaire-12 
(GHQ-12)
A measure of severity of mental problems over the past few weeks
Stroke and Aphasia Quality of Life-39 
(SAQoL-39)
Stroke-aphasia specfic measure of quality of life
European Quality of Life Scale (EQ-5D) An assessment of general quality of life for purposes of health economic 
analyses, and generation of health utilities that can be used to place 
aphasia burden in the context of other stroke related impairment. This 
measure is often used in other stroke contexts and will serve as 
a corresponding measure within an apahsia context through which 
comparisons between different stroke impairment populations can be 
made.
The Subjective Index of Physical and 
Social Outcome (SIPSO)
A measure of societal participation
Modified Rankin Scale (mRS) A measure of independence. This measure is often used in other stroke 
contexts and will serve as a corresponding measure within an apahsia 
context through which comparisons between different stroke impairment 
populations can be made.
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Figure 1. Study overview and data acquisition sources.
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(1) Embedding and Accessing Data Items in Routinely Collected Data
The UK, Sweden and Australia have established registries that routinely collect data on 
stroke admissions for clinical audit. Certain baseline demographic data are already routi-
nely collected within these audits, and the addition of assessments in keeping with the 
I-PRAISE protocol is feasible. Data from these audits will be used to screen for eligible 
participants, with patients consented in the chronic phase. Baseline demographic data 
and pre-recruitment SLT therapies will be retrospectively described; ongoing SLT thera-
pies and outcomes will be prospectively assessed (see Figure 1).
(1) Embedding and Accessing Data Items in Routinely Collected Data
Studies that offer an experimental SLT intervention are appealing for funders and parti-
cipants alike; collaborators will embed I-PRAISE demography and clinical assessments 
along with study-specific data collection within such planned studies. Where recruitment 
is feasible in an acute stroke setting, demographic, clinical and outcome data will be 
prospectively collected. Where recruitment occurs in a chronic setting, baseline demo-
graphy and pre-recruitment SLT regimens will be retrospectively collected from therapy 
and medical notes, and outcomes will be prospectively assessed (see Figure 1).
All 3 data acquisition designs will follow the procedures outlined below.
Setting
This study will be conducted in participating hospitals, outpatient clinics, primary care 
centres, rehabilitation centres and nursing homes with available SLT services, across all 
participating countries. We welcome expressions of interest in the participation of addi-
tional sites and countries.
Sites
Individual sites within each country will be identified as those having the capacity to 
provide SLT services following stroke and have agreed to collect data for I-PRAISE 
according to the standardised protocol and data collection form.
Participants
Whilst we aim to be as inclusive as possible, we acknowledge that some severely impaired 
participants may lack the capacity to consent to inclusion in I-PRAISE, or their comorbid-
ities may present an obstacle to participation. People will be considered for inclusion in 
I-PRAISE if they meet the following criteria:
● Clinical diagnosis of stroke resulting in aphasia, confirmed by assessment using 
standard practice at participating sites.
● Informed consent provided by the patient (facilitated by accessible materials, where 
appropriate) and, if required, by their legal advisor, according to the standard 
procedures in operation at the participating site.
● Able to participate in the assessment protocol for at least 30 minutes during the first 
assessment.
● Accurate documentation of time between stroke and initial assessment.
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Exclusion criteria:
● Language impairment due to an aetiology other than stroke.
● Dysarthria alone.
● Uncorrected severe vision/hearing impairments.
● Pre-stroke clinical diagnosis of dementia.
● Severe neurological or cognitive conditions that preclude assessment or engage-
ment with standard therapy.
● Known life-threatening illness that is likely to lead to death in the next 6 months.
Involvement in concurrent aphasia/stroke intervention studies will not impact on screen-
ing for feasibility of inclusion in I-PRAISE.
Details of intervention and control
I-PRAISE will not investigate a study-mandated experimental SLT intervention. 
Conventional/Usual therapy will be documented via a standardised protocol.
Recruitment
All stroke survivors at participating sites will be screened for eligibility for inclusion in 
I-PRAISE on first contact with SLT services, in an acute setting or in a chronic setting. We 
will impose no restrictions on the time frame from index stroke to study inclusion in order 
to capture information on usual practice for the time to contact with SLT following stroke. 
Each country’s coordinator will engage with SLTs who will be responsible for screening 
and therapy delivery. Coordinators will establish study teams who will share information 
and conduct training with clinicians on eligibility criteria and use of the assessment tools 
where necessary. Screening for eligibility will take place at first contact with the therapist 
for assessment of aphasia after stroke, or as near as possible to this date. The therapist will 
then provide every potential participant or their representative with the Participant 
Information Sheet (PIS), and a “Notification of Interest” form. Participants will be given 
a minimum of 24 hours to consider participation. Those who would like to participate in 
the study will be asked to complete the Notification of Interest form and return it to the 
screening clinician. The number of and reasons for non-inclusions will be recorded on 
a recruitment log.
Capacity to consent
Prior to inclusion in the study, written or oral informed consent will be obtained from each 
participant (or the participant’s legally accepted representative) according to the ethics, 
regulatory and legal requirements of the participating country and site. Those participants 
who agree to be included in the study will be consented by a member of the clinical team 
who has been assigned the responsibility of obtaining consent from participants at that 
centre and will involve the use of accessible information sheets and forms. The participant 
will be informed that their medical records may be examined by authorised monitors or 
by the appropriate Independent Ethics Committee (IEC)/Institutional Review Board (IRB) 
members.
Those participants who are able to be screened and consented in acute settings will be 
recruited. If consent and recruitment are not practical in an acute setting, then patients 
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can be approached in a chronic setting, with retrospective collection of baseline demo-
graphic data, where appropriate.
Assessments
Data will be collected using standardised assessment tools available in a range of 
languages including English, Spanish, German, Swedish, Portuguese, Dutch, Norwegian, 
Greek, Finnish and Maltese, where appropriate adaptations exist. Where adaptations are 
required, teams within each country will explore available options for adaptation prior to 
commencement.
The primary outcomes are the Amsterdam Nijmegen Everyday Language Test (ANELT 
(Blomert, 1992)/Scenario Test (Van Der Meulen et al., 2010)) at 12 months following stroke.
Secondary outcome measures are the Therapy Outcome Measure (TOMS), Subjective 
Index of Physical and Social Outcome; SIPSO (Trigg & Wood, 2000), Aphasia Severity 
Rating Scale (ASRS) of the Boston Diagnostic Aphasia Examination (Goodglass et al., 
2019)/Western Aphasia Battery-Aphasia Quotient (WAB-AQ) (Crary & Gonzalez Rothi, 
1989), European Quality of Life Scale; EQ-5D-5 L) (“European Quality of Life Scale,” 
2011), Stroke and Aphasia Quality of Life Score (SAQoL-39) (Hilari et al., 2003), General 
Health Questionnaire (GHQ-12 (GL Assessment, 2019)), modified Rankin Scale [mRS 
(Bonita & Beaglehole, 1988)], and satisfaction with therapy provision (Revicki et al., 
2008) at 6 and 12 months post-stroke (Table 1: Description of assessment tools; Table 2: 
Schedule of measurements).
Baseline assessment
Following receipt of consent to participate, demographic data will be recorded. This will 
include age, sex, medical history, stroke and aphasia severity, functional communication, 
languages spoken, years of education, handedness, ethnicity, employment status, living 
arrangements, presence of cognitive impairment and presence of motor impairment; time 
since stroke to inclusion in I-PRAISE will also be documented (Table 2; schedule of 
assessments).
Commencement of therapy
Therapy commencement will be defined as the point at which routine aphasia therapy 
commences. We will also note whether advice and education were provided prior to this 
session. Consent for inclusion in the study can occur after the commencement of therapy.
We will collect data on the treatment received at each site and across each health 
service as people move through their recovery. Therapy data will be collected by the 
person delivering the treatment at each session. This will describe the intervention, 
duration, frequency, outcome measurements and discharge destination. Language 
assessments will be carried out by a SLT/trained research assistant, as appropriate.
Completion of treatment will be defined as the point at which the participant is 
discharged from standard SLT.
Discharge
Where discharge from standard SLT occurs prior to the first scheduled follow-up 
(6- month post- index stroke), we will collect data on the discharge destination, ASRS & 
Bedside WAB-AQ, ANELT/Scenario Test & TOMS. Where the 6-month assessment occurs 
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within 4 weeks of SLT discharge, a single 6-month assessment will be conducted. Should 
the participant be re-referred for speech and language therapy, the subsequent therapy 
will be added to their original records whilst retaining the original follow up assessment 
schedule.
Follow up: 6 and 12 months post-stroke
Where applicable, participants will be followed up in the site as part of a study-specific 
speech and language therapy review. The assessor will make a note of the status of the 
participant (alive and participating/alive but unable to participate at this follow-up point/ 
alive but withdrawn from study/lost to follow up/deceased). At both follow-up time 
points, the assessor will systematically document ASRS/WAB-AQ, ANELT/Scenario Test & 
TOMS. ANELT/Scenario Test will be audio-/video recorded for offline blinded analysis, 
where appropriate and according to individual site ethical permissions. Where centralised 
adjudication is not possible, the assessor will complete the scoring locally, and this will be 
noted. Presence of cognitive impairment (using standard practice at each site) and 
functional dependency (mRS) will be described. A research assistant attached to the 
study will contact the participant/carer in writing and follow up with a phone call to 
collect data on participants’ use of support/third sector local services. We will request 
permission to contact the group for a description of the services that they provide. We will 
issue a survey to third-sector organisations to ask about the components of support that 
they provide. Information relating to resource utilisation will be obtained from the 
participant and linked administrative medical records, when available. This will include 
general practitioner visits, hospital and rehabilitation admissions, outpatient and com-
munity service use, medication use for anxiety and depression, speech and language 
therapy, use of speech aids and devices, employment status, respite care and informal 
care as a result of stroke via a standardised resource utilisation questionnaire. Unit prices 
from each country for the different resource use items will be obtained. Finally, we will 
capture impact of, and participant satisfaction with therapy at 6 and 12 months using 
a Likert scale (Revicki et al., 2008).
Neuroimaging
A repository of brain imaging data will accompany the clinical registry data, and will 
permit where available, an examination of the correlation between lesion size/pattern at 
the time of study inclusion with a number of linguistic variables. These include (i) aphasia 
severity and profile prior to therapy and (ii) language outcome at 6 and 12 months. All 
stroke patients undergo clinically motivated imaging on acute admission to hospital. 
Imaging modality varies across participating countries. An estimated 30% will receive 
additional follow-up scanning and MRI is performed in 30–40% of patients. Based on 
estimates from previous smaller scale randomised controlled studies with retrospective 
collections of routinely available brain images early after stroke (Baumgaertner et al., 
2013; Breitenstein et al., 2017; Godecke et al., 2016) and respecting the fact that lesion 
delineation is not possible in very early acute standard CT-imaging (Gonzalez & 
Schwamm, 2016) we expect that lesion site can be determined in 60% of the patients 
included. This will yield a data bank containing the imaging of approximately 2800 
patients of variable modalities (60/40% CT/MRI) with aphasia. The data will be collected 
within national framework structures where available (Germany, UK, Australia and 
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Portugal); data analysis will be carried out by a central brain imaging data-managing team 
(Principal Investigator: Hellmuth Obrig, University Clinic Leipzig, Germany). Personal 
information on the patient will be anonymised prior to transfer. A local coordinator will 
retrieve images and transfer them to the central brain-imaging site in Leipzig (GER). 
Images will be reviewed, converted into NIfTI-format and transferred to the central data 
bank. The team at the central brain imaging site will process the data to yield a repository 
of lesion masks normalised to Montreal Neurological Institute (MNI) space (Collins et al., 
1994) using statistical parametric mapping (SPM) (“NeuroImaging Tools & Resources 
Collaboratory,” 2019) and existing toolboxes (see Figure 2). This will allow for further 
analyses using pattern classification and correlation with behavioural data on patho- 
linguistic profile and therapy outcome measures. A consortium with representatives 
from all participating nations will steer the analysis strategy.
Pharmacological data
Medication data will be recorded from the participant, family member/carer or obtained 
from routinely collected, linked data, if feasible. Medication data prescribed after the 
Figure 2. Development of a neuroimaging repository.
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stroke to treat comorbidities (e.g., epilepsy, depression) and the addition of pharma-
cotherapy or other treatment approaches (e.g., Transcranial Direct-Current Stimulation 
[tDCS]) to improve language deficits will be recorded.
Blinded outcome assessment
Where local ethical regulations permit, we will apply blinded adjudication of the primary 
outcome. For instances when ethical regulations prohibit centralised adjudication, assess-
ments will be carried out by a trained assessor blinded to the nature/content of therapy, 
where appropriate.
Centralised adjudication
Where feasible, we will adapt an existing online platform (McArthur, 2014) for assessment 
of one of our primary outcomes (Amsterdam Nijmegen Everyday Language Test [ANELT]/ 
or Scenario Test for non-verbal participants). Within this system, video/audio recordings of 
participant interviews can be anonymised and securely uploaded to the centralised 
system and distributed to blinded assessors to determine scores for each of the required 
assessment tools. These scores are then entered into the anonymised participant record. 
The aim is not to blind assessors to interventions as there is no active intervention, but to 
enable consistent scoring.
Data management & security
The Robertson Centre for Biostatistics (RCB), Glasgow, UK, will develop an electronic Case 
Report Form (e-CRF) for I-PRAISE. This will be available via a secure online portal where 
clinicians can enter data directly. Where local ethical regulations do not permit the use of 
non-departmental electronic devices, we will provide paper copies of the case report form 
(CRF) for data collection during the therapy session. These data will then be entered into 
the e-CRF by the clinician/research assistant, as appropriate. Only anonymised data will be 
entered into the analysis dataset. Data from each participating site will be uploaded 
directly using the e-CRF. Local coordinators will be granted access to data from their 
respective countries to check on completeness of data, acceptable ranges for variables 
and coding errors. The verified and cleaned data will be entered into a master dataset 
comprising all eligible participants from each country.
Each country will retain its own data and share a copy for the centralised I-PRAISE 
database. All data entered into the I-PRAISE database will be stored at the RCB, University 
of Glasgow, UK and will adhere to national/international data sharing regulations. These 
data will be backed up nightly according to RCB procedures. The primary datasets (as 
entered by respective clinicians) will be preserved unmodified. Primary datasets, the 
master dataset, any other datasets created for this project and analyses datasets will be 
accessed only by the I-PRAISE project management group. The centralised data will not be 
accessible to those outside of the project collaboration.
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Monitoring
At each site quality assurance and verification of variables will be performed by cross- 
checking the dataset against the data sources, checking the acceptable ranges of vari-
ables and through correspondence with the principal investigators (PIs). This will be 
undertaken by local coordinators for each country. External verification will take place 
by examining data ranges, missing variables and through communication with PIs. 
Missing data and reasons for missing data will be verified by the local coordinating 
centres, and where possible we will attempt to retrieve missing data.
A Steering Committee will be formed comprising representatives from each participat-
ing country. The Steering Committee will be responsible for the day-to-day oversight of 
the study. The PIs for each site will be responsible for enrolment, data collection and 
follow-up each site. The Steering Committee will appoint a writing committee for dis-
semination activities.
Serious adverse events that are experienced by participants during the course of the 
study will be documented in the e-CRF for information only. The PIs for each country will 
monitor and report on recruitment within their country to inform progress and ensure 
that recruitment targets for each country are met.
Sample size calculations
We will enrol a minimum of 100 participants from each participating country, with the 
exception of smaller nations (such as Malta < 500,000 inhabitants), where sample sizes will 
take into consideration the size of participating centres; our aim is to be inclusive. Each 
site’s involvement will be guided by a PI from the local Higher Education Institution (HEI) 
collaborator or clinical setting, as appropriate. All participating sites will follow the 
I-PRAISE protocol, but may address additional objectives as will be outlined in their 
country-specific ethics application.
Based on existing annual referrals to participating sites for post-stroke aphasia rehabi-
litation, our liberal eligibility criteria and pragmatic enrolment estimates (estimating 
recruit over 2 years), our baseline sample size is expected to exceed 3000 IPD; exemplar 
estimates available include for the UK (n = 1000), Spain (n = 150), Germany (n = 1250), 
Finland (n = 450), Australia (n = 1167), Netherlands (n = 410), Chile (n = 250), Sweden 
(n = 350), and Portugal (n = 550).
Analysis
Our primary outcome is a change from baseline in the ANELT/Scenario Test at 12-months 
post-stroke. Secondary outcomes at 6 and 12 months include SIPSO, ASRS/WAB-AQ, 
SAQoL-39, EQ-5D, lesion size and site distribution, GHQ-12, resource use, and impact 
satisfaction with therapy provision (Revicki et al., 2008).
IPD meta-analyses will be performed and reported in accordance with the 
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) state-
ment, including data from each country as they become available. Continuous data will be 
reported as median [interquartile range/IQR], categorical data as N (%). A p-value of ≤ 0.05 
will be taken as significant for each outcome. All tests will be two-sided. Details on 
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population size, healthcare types and whether they are high- or low-middle income 
countries will be included as random or fixed effects within the modelling to account 
for differences due to setting. Where large differences in setting are detected, subgroup 
analyses will inform estimates within setting types.
Population who access aphasia therapy
We will extract participants’ population demographic data, presenting age, initial stroke 
severity, time between stroke and first assessment by a speech and language therapists, 
and initial severity of aphasia by ASRS/WAB-AQ as medians and IQRs. We will present all 
summary data (demography, co-morbidities, and living context) stratified by data acquisi-
tion source.
Clinical practice for treatment of aphasia
We will summarise the therapies delivered for aphasia, stratified by country and data 
acquisition source, describing demographic factors. This summary will include detailed 
descriptions of the components of care, the care pathways, the destination of referrals 
and the involvement/availability of community and third-sector support. Where third- 
sector support exists, we will also provide a description of the components of care and 
support that are provided by these third-sector organisations, describing demographic 
characteristics of participants who access these resources, where possible. We will for-
mally examine these associations using regression analyses, adjusting for confounders. 
Summary statistics will include age, sex, time since stroke, duration, dosage and frequency 
of therapy for each participating site/country (median [IQR]). We will also consider the 
impact of treatment setting for example, using multilevel models.
Relationship between different therapies and aphasia outcomes
Where possible, we will categorise each identified aphasia therapy using stroke and 
aphasia care pathways, and informed by categorisations developed in previous work 
from the Collaboration of Aphasia Trialists (On behalf of the RELEASE Collaborators, 
2021) as a guideline. We will describe participants according to verbal and non-verbal 
status at 12 months. Minimal detectable change and clinically important changes from 
baseline the ANELT or Scenario Test at 12-months post-stroke will be examined. Where 
possible, we will examine the trajectory of early spontaneous aphasia recovery using 
methods such as existing prognostic models (Godecke et al., 2013), multi-level models, or 
analysis of pre-treatment ANELT/Scenario Test scores from those who were included in 
I-PRAISE at various time points within one month of the index stroke. Outcomes will be 
assessed using for example, paired analyses of pre- and post-intervention measures to 
assess changes in the ANELT/Scenario Test at individual and population levels.
We will use Generalised Linear Models (GLM) to examine the associations between 
therapy, service level differences and various outcome measures at 6 months and 
12 months following stroke, adjusting for potential confounding factors such as age, 
initial stroke severity, initial aphasia severity, co-morbidities and socio-economic status. 
Analyses will explore whether demographic factors add further predictive value to 
language outcome. Subgroup analyses will examine the association between engage-
ment with third-sector services and aphasia outcomes.
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Aphasia outcomes across different countries
We will describe demographics, therapy differences and outcomes across different coun-
tries using summary statistics, stratified by data acquisition source.
Participants’ perceptions of aphasia services and their ability to cope with post stroke 
aphasia at 12 months
Participants’ perceptions and satisfaction with care will be assessed using a 5-point 
Likert scale (Revicki et al., 2008). We will describe inter-country differences between 
participants and use descriptive statistics to summarise their perceptions of care.
Resource use and the costs of treatment
The costs associated with various aphasia intervention pathways will be described for 
each country and harmonised wherever possible using descriptions of the probability of 
different resources use items and use of a common currency based on conversion with 
appropriate purchasing power parities (Organisation for Economic Cooperation and 
Development, 2019) and reference year. Where possible, these data will then be used 
to determine different incremental costs per WAB-AQ improvement (e.g., net costs/ 
Aphasia Quotient [AQ] score gained for effective interventions) for each broad pathway 
of care identified. One-way sensitivity analyses and probabilistic multivariable analyses 
will be used to account for variability in point estimates (e.g., clinical and resource use 
probabilities, prices) to determine their influence on the results. Consideration of local 
contexts, public and private sector funding and program delivery costs will be described.
Neuroimaging analysis
Lesion masks will be obtained from the available imaging and will be normalised to 
standard space (MNI-space). The masks will be correlated with linguistic and epidemiolo-
gic parameters. Based on the cohort size we aim to address previously recognised 
research questions for imaging-based predictions (Godecke et al., 2016). The lesion 
aphasia profile analysis will use standard lesion-symptom-mapping methodology 
(Rorden et al., 2007). Since different imaging modalities are implemented, a binary lesion 
mask will be used for the overall analyses. Lesion size and site will be correlated with 
lesion patterns. The overall goal is to identify brain lesion patterns correlating with long- 
term language functional outcomes (ANELT/Scenario Test) at 12 months post- index 
stroke. Secondary outcomes comprise linguistic measures as well as therapist’s and 
patient’s ratings of communicative performance. Secondary analyses will target differ-
ences of the predictive strengths depending on imaging modality (CT/different MRI 
protocols) and the time point of imaging (acute/subacute/early chronic stage). 
Subgroup analyses of different therapy regimens (e.g., intensive versus non-intensive) 
are also planned. Additionally, we expect to replicate previously reported lesion-aphasia 
profile correlations (Henseler et al., 2014), and provide data on differences between 
neuroimaging practice in the various national health care systems, to inform optimisation 
of imaging protocols for speech and language therapy service provision. The data will also 
be available to evaluate different analysis strategies (Turken & Dronkers, 2011; Yourganov 
et al., 2016).
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Medication analysis
Multiple linear and multiple logistic regressions will be performed in order to identify 
significant predictors of language recovery in ANELT/Scenario Test, ASRS/WAB-AQ, EQ-5D 
as appropriate. The selection of these independent variables will be made based on 
existing literature, as well as assessment of interactions with demographic or comorbidity 
factors. Independent variables to be incorporated in the model include: medications with 
potentially detrimental effects (e.g., antihypertensives, clonidine, prazosin, anti- 
arrhythmics, adenosine agonists, digitalis glycosides, typical neuroleptics and antimus-
carinic agents), medication with a potentially beneficial effect (e.g. nootropics, dopamine 
agonists, acetylcholinesterase inhibitors, and NMDA receptor antagonists), with adjust-
ment for age, gender, depression score, drug administration, onset phase (acute or 
chronic), and initial aphasia severity.
Missing data
Patterns and the extent of missing data will be explored. For each primary outcome, we 
will perform sensitivity analyses to examine the effects of missing data using multiple 
imputation. We will report on the proportion of outcome data that are genuinely missing 
at follow-up and describe the demographic and clinical factors of this population. We will 
compare this demography with the characteristics of those who completed follow up.
Protocol amendments
No changes (amendments) to the Protocol will be implemented without prior approval 
from the appropriate local Ethics Committee. If a Protocol amendment requires changes 
to the Informed Consent Form, the revised Informed Consent Form, prepared by the PI, 
will be approved by the Ethics Committee.
Discussion
I-PRAISE seeks to produce a high volume of structured data through coordinated, inter-
national application of a shared, standardised protocol. By taking a pragmatic, interna-
tional approach to data acquisition and implementing a standardised protocol, I-PRAISE 
aims to capitalise on the wealth of data already being gathered for research and audit 
purposes. Generating high-quality, standardised international data will inform the deliv-
ery of interventions for aphasia, enable comparison of service delivery, and examination 
of associations between services, aphasia outcomes, resource utilisation/costs and differ-
ence among participant populations who engage and benefit from specific services 
across different countries. I-PRAISE will also contribute to our long-term ambition of 
establishing national clinical registries for post-stroke aphasia outcome and rehabilitation.
Leveraging the collection of patients’ and clinicians’ data is an important way of 
improving quality and efficiency of health care delivery and generating new knowledge 
(Murdoch & Detsky, 2013). Scaling this internationally has the potential to rapidly gen-
erate data on a population with pressing health needs(Everett et al., 2021) in a time 
efficient manner. Currently, rich data that are collected as part of routine care are often 
seen as a by-product of healthcare rather than as an asset to improve health care delivery 
(Murdoch & Detsky, 2013). I-PRAISE aims to capitalise on routinely collected data in the 
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international context in the form of participant demographics, clinical measurements, 
intervention descriptions, neuroimaging and medication review, and supplement these 
with collection of data in a core outcome set immediately after the SLT intervention as 
well as at 6- and 12-months post-stroke. The cost of answering many clinical questions by 
conducting paired randomised comparisons and collecting structured data in relation to 
complex rehabilitation interventions, outcomes and population is prohibitive (Murdoch & 
Detsky, 2013). The establishment of an international registry comprising those with 
clinical aphasia in I-PRAISE will enable novel exploratory analyses, reflecting a much 
wider clinical population. Data-driven clinical decision support tools may eventually 
lead to improved use of limited resources or cost-savings and help with appropriate 
standardisation of care (Murdoch & Detsky, 2013). I-PRAISE offers the opportunity to 
integrate the traditional medical model with the social care available across multiple 
countries to improve and inform patient-directed interventions, and has the potential to 
inform clinical practice by using information generated in every-day clinical settings to 
inform the quality and efficiency of stroke care (Murdoch & Detsky, 2013).
Limitations include the availability of assessment tools in each of the required lan-
guages. Lack of availability has been highlighted by several countries and work is under-
way to adapt and validate several assessment tools. This has been informed by 
experienced colleagues from the Collaboration of Aphasia Trialists (CATs) (www.aphasia 
trials.org), who are members of a working group specifically developed to facilitate 
adaptation of outcome assessments. We have also identified a need for staggered project 
initiation in order to accommodate such preparatory work, which will increase our time-
lines for analyses. However, staggered project initiation will enable experience to be 
shared, and processes to be refined as more countries commence data collection. 
Additional limitations include the availability of data storage and large-scale research 
support infrastructure across countries and the complexity of international collaboration. 
Concerns can be mitigated through the shared experience of I-PRAISE members, many of 
whom also collaborated on the large-scale RELEASE project (The RELEASE Collaboration, 
2020), which collated and meta-analysed data from 174 international aphasia research 
datasets.
Advantages include (i) standardised description of the clinical aphasia population 
(demographics, language characteristics and comorbid stroke symptoms) (ii) description 
of the capacity for speech and language therapy provision and aphasia support across the 
recovery trajectory (components of care, care pathways, and involvement of third sector 
organisations) and across countries; (iii) identification of rehabilitation factors (type, 
delivery models, dosage) that are associated with good functional communication and 
participation outcomes, accounting for stroke and aphasia profiles (iv) identification of the 
subpopulations of people with aphasia who appear to have good outcomes and identi-
fication of those in whom more support is needed (those with poor outcomes despite 
access to support), (v) identification of the neuroanatomical correlates of good language 
outcome and (vi) description of the costs associated with current clinical interventions.
Analyses from this international, multilingual, multicultural dataset will help to inform 
research into two of the James Lind Alliance’s top 10 research priorities for life after stroke 
(Pollock et al., 2012) and will address pivotal issues surrounding aphasia recovery at an 
international level, including description of the amount of recovery observed, the condi-
tions under which this recovery occurs, and the state of aphasia therapy internationally. 
18 M. ALI ET AL.
International health and outcome data will be used to describe associations between 
aphasia interventions and quality of life (EQ-5D), inform calculation of international health 
utilities for post-stroke aphasia populations, and provide indications of costs and subse-
quent outcomes for currently used interventions. Analyses will enable both within and 
between-country examination of outcomes, indicating areas that need improvement, 
highlighting practices that may work well across similar settings, and identifying geo-
graphic factors that are associated with better quality of life following aphasia. We 
welcome further countries wishing to join in this collaboration.
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